TheStreet’s Jim Cramer says the Shire-NPS Pharmaceuticals deal is a verification of the strategy that many biotechs have. Cramer says he has interviewed NPS CEO Francois Nader a number of times and Nader has always said that its orphan drug strategy is a winner. Cramer says now that strategy is paying off. He explains that what he likes about NPS is that they make treatments for rare diseases and that they’re not tethered to any other drugs. He adds that Shire coming in with this huge bid verifies the whole orphan drug segment of biotechs. Irish drugmaker Shire agreed to buy U.S. group NPS Pharmaceuticals for $5.2 billion in an all-cash deal. This is Shire’s biggest acquisition so far as it tries to boost its portfolio of medicines for rare conditions.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
